Four new Substance values were added to code table XW0, Anatomical Regions, Introduction, as follows:
|A Bezlotoxumab Monoclonal Antibody|
|B Cytarine and Daunorubicin Liposome Antineoplastic|
|C Engineered Autologous Chimeric Antigen Receptor T-Cell Immunotherapy|
|F Other New Technology Therapeutic Substance|
Bezlotoxumab, also known by its brand name ZINPLAVA, is used to treat patients who are already receiving an antibiotic for Clostridium difficile infection but who are at high risk for recurrence. Rather than targeting the Clostridium difficile bacteria itself as the antibiotic does, Bezlotoxumab is a monoclonal antibody that targets toxins produced by the Clostridium difficile bacteria, and is administered intravenously.
Cytarine and Daunorubicin
Cytarabine and Daunorubicin Liposome for Injection uses the brand name VYXEOS. Cytarine and Daunorubicin are existing chemotherapy drugs that are commonly used in a concurrent dosing regimen to induce remission of acute myeloid leukemia. VYXEOS is a specific formulation that combines the two drugs. It is administered intravenously.
Engineered Autologous Chimeric Antigen Receptor T-Cell Immunotherapy
KTE-C19 is also known as axicabtagene ciloleucel. This is an engineered autologous immunotherapy. It is used to treat patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma who are ineligible for an autologous stem cell transplant. The patient’s own T-cells are harvested and engineered using a “chimeric antigen receptor construct” to target specific antigens associated with B-cell lymphoma. After being infused back into the patient, the T-cells find their target cells and kill them.
Other New Technology Therapeutic SubstancesIn code table XW0, the value “F” Other New Technology Therapeutic Substance was also added to the rows for the body part values describing Central and Peripheral Vein. This value can be assigned for new technology intravenous drugs when no specific code exists.